Supplementary Table 1: Menopausal hormone therapy use and risk of incident fecal incontinence – full model

Covariate	Multivariate-adjusted HRs (95% CI) [a]
MHT use status (compared to never users)	
Current	1.32 (1.20-1.45)
Past MHT use	1.26 (1.18-1.34)
Race (compared to white women)	
Black	0.82 (0.64-1.06)
Other	1.15 (1.03-1.28)
Age at menopause (compared to ≥53 years old)	
<44 years old	1.11 (0.99-1.24)
44-46 years old	1.08 (0.97-1.20)
47-49 years old	1.05 (0.95-1.16)
50-52 years old	1.00 (0.93-1.08)
BMI, kg/m^2 (compared to 20-24.9)	
<20	1.13 (1.03-1.24)
25-29.9	1.00 (0.94-1.06)
≥30	1.09 (1.02-1.17)
Leisure time exercise (compared <4 METs[a])	
4-7 METs	0.92 (0.84-1.00)
≥8 METs	0.88 (0.83-0.93)
Smoking status (compared to never smokers)	
Past	1.01 (0.96-1.06)
Current	1.13 (1.01-1.27)
Age at menarche (compared to 12 years old)	
≤10 years old	1.04 (0.93-1.17)
11 years old	1.01 (0.94-1.09)
13 years old	1.03 (0.97-1.10)
≥14 years old	1.05 (0.98-1.13)
Ever used oral contraceptives (compered to never users)	1.07 (1.01-1.13)
Parity (compared to nulliparous women)	
1	1.23 (1.06-1.43)
2	1.30 (1.14-1.47)
3+	1.41 (1.25-1.59)
Surgical/radiation-induced menopause (compared to natural menopause)	1.10 (1.04-1.17)
Diabetes mellitus	1.40 (1.31-1.51)
Hypertension	1.09 (1.04-1.15)
Neurologic disease[b]	1.69 (1.51-1.90)
History of cholecystectomy	1.23 (1.16-1.31)
Total number of years working night shifts	1.01 (0.99-1.02)

[a] MET= metabolic equivalent of task

[b] Defined as a confirmed diagnosis of amyotrophic lateral sclerosis, multiple sclerosis, or Parkinson's disease